A Phase 3 interventional study of Amphetamine Sulfate and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Arbor Pharmaceuticals, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-09-03.
Sponsored by Arbor Pharmaceuticals, Inc. (part of Azurity Pharmaceuticals) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 70th largest by enrollment of the 706 interventional ones that give a count, is one of 37 that started in 2018, is one of 121 in phase 3, and was the 544th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 37 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 320 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
This study is registered under Arbor Pharmaceuticals, Inc., one of the names counted as Azurity Pharmaceuticals. Under that name alone:
Arbor Pharmaceuticals, Inc. is the lead sponsor of 15 studies on the registry; none are open to participants now.
Azurity Pharmaceuticals has 3 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)
This is a randomized, fixed-dose, double-blind, multicenter trial to investigate the safety and efficacy of AR19 in the treatment of ADHD in adults from 18 through 55 years of age. Safety parameters and therapeutic effect will be evaluated throughout the trial. A target of 312 subjects is set for enrollment. Once subjects are determined to meet all inclusion criteria and were screened, they will be randomized to 20 or 40 mg AR19 daily or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Males and females who are fertile and sexually active with a partner of the opposite sex must adhere to requirements for the duration of the study as follows:
Exclusion Criteria:
Has a history of any of the following disorders:
Subjects who have had gastrointestinal surgery or a procedure that involves:
Has (ECG) or clinical evidence of the following:
Has an abnormal laboratory test value, vital sign, or other exam finding at Screening or Baseline that, in the opinion of the Investigator, warrants exclusion from the study. In addition, subjects with laboratory values listed below are considered exclusionary:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amphetamine Sulfate
Drug: Amphetamine Sulfate
Amphetamine Sulfate
Drug: Amphetamine Sulfate
Placebo, no active drug
Drug: Placebo
active experimental AR19
Also known as: AR19
Matching placebo
Also known as: inactive drug
Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms
Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.
Time frame: Week 5 (Visit 7)
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
Items are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.
Time frame: Up to 5 weeks
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
CGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
Time frame: Up to 5 weeks
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
"Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."
Time frame: Up to 5 weeks
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.
Time frame: Up to 5 weeks
| Milestone | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Started | 106 | 107 | 107 |
| Completed | 92 | 87 | 87 |
| Not completed | 14 | 20 | 20 |
Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.
| score on a scale | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms | -11.1 ± 1.28 | -18.2 ± 1.28 | -18.1 ± 1.27 |
Items are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.
| score on a scale | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Hyperactivity/Impulsivity Subscale | -5.2 ± 0.61 | -8.3 ± 0.61 | -8.0 ± 0.6 |
| Inattentive Subscale | -5.9 ± 0.74 | -9.9 ± 0.74 | -10.0 ± 0.74 |
CGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.
| score on a scale | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Visit 3 (Week 1) | -0.5 ± 0.1 | -0.9 ± 0.1 | -1.0 ± 0.1 |
| Visit 4 (Week 2) | -0.7 ± 0.12 | -1.1 ± 0.12 | -1.3 ± 0.12 |
| Visit 5 (Week 3) | -0.8 ± 0.12 | -1.4 ± 0.12 | -1.5 ± 0.12 |
| Visit 6 (Week 4) | -0.8 ± .12 | -1.4 ± .12 | -1.5 ± 0.12 |
| Visit 7 (End of Study/End of Treatment) | -0.9 ± .13 | -1.5 ± .13 | -1.5 ± .13 |
"Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."
| score on a scale | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Visit 3 (Week 1) | 3.3 ± 0.1 | 2.9 ± 0.1 | 2.8 ± 0.1 |
| Visit 4 (Week 2) | 3.2 ± 0.11 | 2.6 ± 0.11 | 2.4 ± 0.11 |
| Visit 5 (Week 3) | 3.0 ± 0.11 | 2.6 ± 0.11 | 2.4 ± 0.11 |
| Visit 6 (Week 4) | 3.1 ± 0.11 | 2.5 ± 0.11 | 2.4 ± 0.11 |
| Visit 7 (End of Study/End of Treatment) | 3.1 ± 0.12 | 2.5 ± 0.12 | 2.4 ± 0.12 |
The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.
| T-Score | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| Global Executive Composite T-Score | -7.4 ± 1.33 | -13.6 ± 1.35 | -14.6 ± 1.31 |
| Behavioral Regulation Index T-Score | -6.4 ± 1.15 | -11.5 ± 1.17 | -12.8 ± 1.14 |
| Metacognition Index (MI) T-Score | -7.2 ± 1.32 | -13.4 ± 1.37 | -14.2 ± 1.33 |
| Inhibit T-Score | -7.1 ± 1.22 | -11.3 ± 1.25 | -13.0 ± 1.21 |
| Self-Monitor T-Score | -5.2 ± 1.10 | -10.6 ± 1.12 | -11.9 ± 1.09 |
| Plan/Organize T-Score | -6.9 ± 1.30 | -12.2 ± 1.33 | -12.9 ± 1.29 |
| Shift T-Score | -4.8 ± 1.13 | -9.8 ± 1.16 | -10.4 ± 1.13 |
| Initiate T-Score | -5.0 ± 1.16 | -10.3 ± 1.19 | -11.2 ± 1.15 |
| Task Monitor T-Score | -6.8 ± 1.33 | -12.6 ± 1.36 | -13.5 ± 1.32 |
| Emotional Control T-Score | -3.9 ± 0.94 | -7.1 ± 0.96 | -8.0 ± 0.93 |
| Working Memory T-Score | -7.5 ± 1.36 | -13.4 ± 1.40 | -14.8 ± 1.36 |
| Organization of Materials T-Score | -4.3 ± 1.09 | -9.5 ± 1.12 | -10.0 ± 1.09 |
Collected over Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/106 (0%) | 0/106 (0%) | 19/106 (17.9%) |
| Amphetamine Sulfate (20 mg/Day) | 0/107 (0%) | 0/107 (0%) | 46/107 (43%) |
| Amphetamine Sulfate (40 mg/Day) | 0/107 (0%) | 0/107 (0%) | 55/107 (51.4%) |
| Event | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) |
|---|---|---|---|
| HeadacheNervous system disorders | 13/106 | 14/107 | 12/107 |
| Decreased AppetiteMetabolism and nutrition disorders | 5/106 | 11/107 | 14/107 |
| Dry MouthGastrointestinal disorders | 4/106 | 6/107 | 12/107 |
| InsomniaPsychiatric disorders | 4/106 | 9/107 | 10/107 |
| PalpitationsCardiac disorders | 2/106 | 2/107 | 7/107 |
| NasopharyngitisInfections and infestations | 6/106 | 5/107 | 3/107 |
| TachycardiaCardiac disorders | 0/106 | 6/107 | 4/107 |
| Age, Continuous(years) | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) | Total |
|---|---|---|---|---|
| Mean | 34.2 ± 10.75 | 35.6 ± 10.28 | 33.5 ± 9.35 | 34.4 ± 10.15 |
| Sex: Female, Male(Participants) | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) | Total |
|---|---|---|---|---|
| Female | 52 | 50 | 44 | 146 |
| Male | 54 | 57 | 63 | 174 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 14 | 13 | 14 | 41 |
| Not Hispanic or Latino | 92 | 94 | 93 | 279 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 6 | 1 | 2 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 1 |
| Black or African American | 13 | 13 | 15 | 41 |
| White | 80 | 89 | 88 | 257 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 4 | 1 | 11 |
| ADHD Type(Participants) | Placebo | Amphetamine Sulfate (20 mg/Day) | Amphetamine Sulfate (40 mg/Day) | Total |
|---|---|---|---|---|
| Inattentive | 14 | 19 | 20 | 53 |
| Hyperactive/Impulsive | 1 | 0 | 0 | 1 |
| Combined | 91 | 88 | 87 | 266 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2018 to primary completion in Apr 2019, 6 months.
Results were first posted in Sep 2024, 5 years 4 months after primary completion. A results delay was requested in Aug 2020.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amphetamine
Attention Deficit Disorder with Hyperactivity →